CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:



(I)

Wherein:

Y is selected from hydrogen, hydroxyl, -NH_2, -NH-C_{1-4}-alkyl, -NH-halo-C_{1-4}-alkyl, or-C_{1-4}-alkoxy; Z is selected from hydrogen, halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4} alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$(-$S0_2NH_2$, -NH_2, -$NHC_{1.4}$-alkyl, or -NHhalo-$C_{1.4}$-alkyl; R^1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, $C_{1.4}$-alkyl, halo-$C_{1.4}$-alkyl, cyano-C_{1-4}-alkyl, a 3-7 membered cycloalkyl ring, -OR^5, -$NR^6C(0)0R^5$, -$NR^6C(0)R^5$, -$NR^6C(0)NR^4AR^4B$, -$C(0)NR^4AR^4B$, -$C(0)R^5$, -$C(0)0R^5$, and-$NR^6S(0)_2R^5$; wherein R^{4A}, R^{4B} $R^5$and R^6 are each independently selected from hydrogen, $C_{1.4}$-alkyl or halo-C_{1-4}-alkyl, or R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo$C_{1.4}$-alkoxy, -$CONH_2$, -$S0_2NH_2$| -NH_2, -$NHC_{1.4}$-alkyl, -NHhalo-C_{1-4}alkyl; W is a phenyl ring or a 5 or 6-membered heteroaryl ring selected from pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, oxazolyl, thiazolyl or imidazolyl, any of which rings being optionally substituted with one or more substituents selected from halogen, cyano, oxo, $C_{1.4}$-alkyl, halo-$C_{1.4}$-alkyl, cyano-$C_{1.4}$-alkyl, -OR^5, -$NR^{7A}R^{7B}$, -$NR^6C(0)0R^5$, -$NR^6C(0)R^5$, -$NR^6C(0)NR^{7A}R^{7B}$, -$C(0)NR^{7A}R^{7B}$, -$C(0)R^5$, -$C(0)0R^5$, -SO_2R^5, -$S0_2NR^{7A}R^{7B}$and -$NR^6S(0)_2R^5$; $R^{7A}$and R^{7B} are independently hydrogen, $C_{1.4}$-alkyl or halo-C_{1-4}-alkyl. V is selected from a bond, -0-, -$N(R^6)$-, -(C=0)-, -$CONR^6$-, -$NR^6C(0)$-, or -CM_{1-4} alkylene-, wherein the C_{1-4}lkylene group is optionally substituted by halogen, and wherein any one of the carbon atoms of the C^-alkylene group may be replaced by -O- or -N(R6)-; R3 is selected from hydrogen, -C_{1-4}-alky!, -C_{1-4}-alkyl-$C_{,1-4}$-alkoxy or a 3-7 membered heterocyclic ring

~~or 3-7 membered cycloalkyl ring, or a 5 or 6-membered heteroaryl ring, any one of the rings being optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, $-OR^5$, $-NR^{4A}R^{4B}$, $-NR^6C(0)0R^5$, $-NR^6C(0)R^5$, $-NR^6C(0)NR^{4A}R^{4B}$, $-C(0)NR^{4A}R^{4B}$, $-C(0)R^5$, $-C(0)0R^5$, $-S0_2R^5$, $-S0_2NR^{4A}R^{4B}$ and $-NR^6S(0)_2R^5$; PROVIDED THAT groups $-WVR^3$ and/or R^1 are not:~~



~~wherein~~

~~n is 0,1, or 2; R' and R" are independently selected from the group consisting of H, $-C_1C_6$alkyl, $-(C=0)-C_1-C_6$-alkyl and $-(C=0)0C(CH_3)_3$; and R"' is H, OH, or C_1-C_6-alkyl.~~

~~1.~~ A pharmaceutical composition comprising a compound of formula (Xa)



wherein E is —C═ or —N═,

R^9 and R^{10} are each independently one or more substituents selected from hydrogen, halogen, cyano, oxo, C_{1-4}-alkyl, —OC_{1-4}-alkyl and halo-C_{1-4},-alkyl;

R^{11} is one or more substituents selected from hydrogen, halogen, cyano, cyclopropyl, C_{1-4}-alkyl, and halo-C_{1-4}-alkyl;

or a pharmaceutically acceptable salt thereof, and one or more suitable excipients.

2. ~~A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:~~



(I)

~~Wherein:~~

Y is selected from hydrogen, hydroxyl, -NH_2, -NH-C_{1-4}-alkyl, -NH-halo-$C_{1.4}$- alkyl, or -$C_{1.4}$-alkoxy; Z is selected from hydrogen, halogen, hydroxyl, cyano, $C_{1.4}$-alkyl, halo-$C_{1.4}$- alkyl, $C_{1.4}$-alkoxy, halo-C_{1-4}-alkoxy, -$CONH_2$, -$S0_2NH_2$- NH_2, -$NHC_{1.4}$-alkyl, or -5 NHhalo-$C_{1.4}$-alkyl; R1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-5}-alkyl, -OR^5, -$NR^6C(0)0R^5$, -$NR^6C(0)R^5$, - $NR^6C(0)NR^{4A}R^{4B}$, -$C(0)NR^{4A}R^{4B}$, -$C(0)R^5$, -$C(0)0R^5$, and -$NR^6S(0)_2R^5$; wherein R^{4A}, R^{4B} R^5 and R^6 are each independently selected from hydrogen, $C_{1.4}$-alkyl or halo-$C_{1.4}$-alkyl, or R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7' membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, $C_{1.4}$-alkyl, halo-C_{1-4}-alkyl, $C_{1.4}$-alkoxy, halo1-4-alkoxy, -$CONH_2$, -$S0_2NH_2$, -NH_2, -NHC_{1-4}-alkyl, -NHhalo-$C_{1.4}$-alkyl; X is -N=; W is a phenyl ring or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, $C_{1.4}$-alkyl, halo-$C_{1.4}$-alkyl, cyano-C_{1-4}-alkyl, -OR^5, - $NR^{7A}R^{7B}$, - $NR^6C(0)0R^5$, - $NR^6C(0)R^5$, - $NR^6C(0)NR^{7A}R^{7B}$, -$C(0)NR^{7A}R^{7B}$, -$C(0)R^5$, -$C(0)0R^5$, -$S0_2R^5$, - $S0_2NR^{7A}R^{7B}$ and -$NR^6S(0)_2R^5$; R^{7A} and R^{7B} are independently hydrogen, $C_{1.4}$-alkyl or halo-$C_{1.4}$-alkyl. V is selected from a bond, -0-, -$N(R^6)$-, -(C=0)-, -$CONR^6$-, -$NR^6C(0)$-, or -$C_{1.4}$- alkylene-, wherein the $C_{1.4}$-alkylene group is optionally substituted by halogen, and wherein any one of the carbon atoms of the $C_{1.4}$-alkylene group may be replaced by -O- or -$N(R^6)$-; R^3 is hydrogen, or a 3-7 membered heterocyclic ring, or 3-7 membered cycloalkyl ring selected from cyclopropyl, cyclopentyl or cyclohexyl, or a 5 or 6-membered heteroaryl ring, any one of the rings being optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, CM-alkyl, halo$_{1,4}$-alkyl, cyano-$C_{1.4}$-

~~alkyl, -OR^5, -NR^{4A}R^{4B}, -NR^{6}C(0)0R^5, -NR^{6}C(0)R^5, -NR^{6}C(0)NR^{4A}R^{4B}, -C(0)NR^{4A}R^{4B}, -C(0)R^5, -C(0)0R^5, -S0$_2$R^5, -S0$_2$NR^{4A}R^{4B} and -NR^{6}S(0)$_2$R^5.~~

A pharmaceutical composition comprising a compound of formula (Xa)



wherein E is —C═ or —N═,

R^9 and R^{10} are each independently one or more substituents selected from hydrogen, halogen, cyano, oxo, C_{1-4}-alkyl, —OC_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{11} is one or more substituents selected from hydrogen, halogen, cyano, cyclopropyl, C_{1-4}-alkyl, and halo-C_{1-4}-alkyl;

or a pharmaceutically acceptable salt thereof, and one or more suitable excipients.

3. ~~A compound according to claim 1 or 2 wherein Y is hydrogen.~~

Use of a compound of formula (Xa)



(Xa)

wherein E is —C═ or —N═,

R^9 and R^{10} are each independently one or more substituents selected from hydrogen, halogen, cyano, oxo, C_{1-4}-alkyl, —OC_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{11} is one or more substituents selected from hydrogen, halogen, cyano, cyclopropyl, C_{1-4}-alkyl, and halo-C_{1-4}-alkyl;

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition or disease wherein inhibition of SSAO activity is beneficial.

4. ~~A compound according to any one of claims 1 to 3 wherein Z is hydrogen.~~

The compound of claim 1, selected from the group consisting of:

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 21);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl} morpholine (Example 22);

(2R,6S)-4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,6-dimethylmorpholine (Example 23);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,2-dimethyl morpholine (Example 24);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl} morpholine (Example 26);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl} morpholine (Example 27);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methoxypyridin-2-yl} morpholine (Example 28);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4,6-dimethylpyridin-2-yl} morpholine (Example 29);

4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 41);

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 47);

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 51);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 52);

4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 53);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 54);

4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 55);

4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 56);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 57);

4-{5-[3-(4-Bromophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 59);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 60);

4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 61);

4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 62);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 63);

4-(5-{3-[4-(Trifluoromethyl)phenyl]-3H-imidazo[4,5-c]pyridin-2-yl}pyridin-2-yl) morpholine (Example 66);

4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 67);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 68);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-2-methylmorpholine (Example 70);

4-{5-[3-(4-Chloro-3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 74);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 77);

4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 78);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 80);

4-(5-{3-Phenyl-3H-imidazo[4,5-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 95);

4-{5-[3-(4-Cyclopropylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 96);

4-{4-Methyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 97);

4-{3-Fluoro-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 98);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(morpholin-4-yl)-1,4-dihydro pyridin-4-one (Example 99);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methylpyridin-2-yl}morpholine (Example 108);

4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 127);

4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 129);

4-{5-[1-(4-Methylphenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 130);

4-(5-{1-Phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 131);

4-{5-[1-(4-Bromophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 133).

5. ~~A compound according to any one of claims 1 to 3 wherein Z is hydrogen.~~

The compound of claim 1, wherein the compound is 4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 57).

6. ~~A compound according to any one of claims 1 to 4 wherein R^1 is phenyl or 6-membered heteroaryl, optionally substituted with one or more substituents selected from halogen, C_{1-4}-alkyl or halo-C_{1-4}-alkyl.~~

The pharmaceutical composition of claim 2, wherein the compound is selected from the group consisting of:

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 21);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl} morpholine (Example 22);

(2R,6S)-4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,6-dimethylmorpholine (Example 23);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,2-dimethyl morpholine (Example 24);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl} morpholine (Example 26);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl} morpholine (Example 27);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methoxypyridin-2-yl} morpholine (Example 28);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4,6-dimethylpyridin-2-yl} morpholine (Example 29);

4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 41);

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 47);

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 51);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 52);

4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 53);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 54);

4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 55);

4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 56);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 57);

4-{5-[3-(4-Bromophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 59);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 60);

4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 61);

4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 62);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 63);

4-(5-{3-[4-(Trifluoromethyl)phenyl]-3H-imidazo[4,5-c]pyridin-2-yl}pyridin-2-yl) morpholine (Example 66);

4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 67);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 68);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-2-methylmorpholine (Example 70);

4-{5-[3-(4-Chloro-3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 74);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 77);

4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 78);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 80);

4-(5-{3-Phenyl-3H-imidazo[4,5-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 95);

4-{5-[3-(4-Cyclopropylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 96);

4-{4-Methyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 97);

4-{3-Fluoro-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 98);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(morpholin-4-yl)-1,4-dihydro pyridin-4-one (Example 99);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methylpyridin-2-yl}morpholine (Example 108);

4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 127);

4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 129);

4-{5-[1-(4-Methylphenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 130);

4-(5-{1-Phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 131);

4-{5-[1-(4-Bromophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 133);

and pharmaceutically acceptable salts thereof.

7. ~~A compound according to any one of claims 1 to 5 wherein R^1 is phenyl or pyridyl, optionally substituted with one or more substituents selected from F, CI or CH_3.~~

The pharmaceutical composition of claim 1, wherein the compound is 4-{5-[3-(4-methyl phenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 57), or a pharmaceutically acceptable salt thereof.

8. ~~A compound according to any one of claims 1 to 6 wherein W is a phenyl ring optionally substituted with one or more substituents as defined in claim 1 or claim 2.~~

The use of claim 3, wherein the compound is selected from the group consisting of:

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 21);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl} morpholine (Example 22);

(2R,6S)-4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,6-dimethylmorpholine (Example 23);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,2-dimethyl morpholine (Example 24);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl} morpholine (Example 26);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl} morpholine (Example 27);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methoxypyridin-2-yl} morpholine (Example 28);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4,6-dimethylpyridin-2-yl} morpholine (Example 29);

4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 41);

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 47);

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 51);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 52);

4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 53);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 54);

4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 55);

4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 56);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 57);

4-{5-[3-(4-Bromophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 59);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 60);

4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 61);

4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 62);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 63);

4-(5-{3-[4-(Trifluoromethyl)phenyl]-3H-imidazo[4,5-c]pyridin-2-yl}pyridin-2-yl) morpholine (Example 66);

4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 67);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 68);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-2-methylmorpholine (Example 70);

4-{5-[3-(4-Chloro-3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 74);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl} morpholine (Example 77);

4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 78);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 80);

4-(5-{3-Phenyl-3H-imidazo[4,5-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 95);

4-{5-[3-(4-Cyclopropylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 96);

4-{4-Methyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 97);

4-{3-Fluoro-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 98);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(morpholin-4-yl)-1,4-dihydro pyridin-4-one (Example 99);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methylpyridin-2-yl}morpholine (Example 108);

4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 127);

4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 129);

4-{5-[1-(4-Methylphenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 130);

4-(5-{1-Phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 131);

4-{5-[1-(4-Bromophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 133);

and pharmaceutically acceptable salts thereof.

9. ~~A compound according to any one of claims 1 to 6 wherein W is a 5- membered heteroaryl ring selected from oxazole, thiazole or imidazole optionally substituted with one or more substituents as defined in claim 1 or claim 2.~~

The use of claim 3, wherein the compound is 4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 57), or a pharmaceutically acceptable salt thereof.

10. The use of claim 3, wherein the condition or disease is inflammation, an inflammatory disease, an immune or autoimmune disorder, cystic fibrosis, or tumor growth

~~A compound according to any one of claims 1 to 6 wherein W is an imidazolyl ring optionally substituted as in claim 1, and wherein the imidazolyl ring is connected to the pyrrolopyridine core via an imidazolyl ring carbon atom.~~

11. The use of claim 3, wherein the condition or disease is arthritis, synovitis, vasculitis, inflammation of the bowel, atherosclerosis, multiple sclerosis, Alzheimer's disease, vascular dementia, a pulmonary inflammatory disease, a fibrotic disease, an inflammatory disease of the skin, systemic inflammatory response syndrome, sepsis, an inflammatory and/or autoimmune

condition of the liver, diabetes, chronic heart failure, congestive heart failure, ischemic disease, myocardial infarction, or epilepsy. ~~A compound according to any one of claims 1 to 10 wherein W is optionally substituted with one or more substituents selected from fluoro, chloro, cyano, CH_3 or CF_3.~~

12. ~~A compound according to any one of claims 1 to 11 wherein V is —CH_2-, —$(CH_2)_2$-, or -$N(R^6)CH2$-, or -CH_2-$N(R^6)$-.~~

A compound of formula (Xa)



wherein E is —C═ or —N═,

R^9 and R^{10} are each independently one or more substituents selected from hydrogen, halogen, cyano, oxo, C_{1-4}-alkyl, —OC_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{11} is one or more substituents selected from hydrogen, halogen, cyano, cyclopropyl, C_{1-4}-alkyl, and halo-C_{1-4}-alkyl;

or a pharmaceutically acceptable salt thereof for use in the treatment of a condition or disease wherein inhibition of SSAO activity is beneficial.

~~13. A compound according to claim 1 or any one of claims 1 to 12 when dependent on claim 1 wherein R^3 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted as defined in claim 1.~~

~~14. A compound according to any one of claims 1 to 11 wherein R^3 is formed from —$NR^{4A}R^{4B}$ wherein R^{4B} and R^{4B}, together with the nitrogen atom to which they are attached join together to form a 4-7 membered heterocyclic ring optionally substituted as defined in claim 1 or claim 2.~~

~~15. A compound according to any one of claims 1 to 11 wherein R^3 is selected from the group consisting of:~~



~~wherein R^8 is selected from hydrogen, CH_3, $CONH_2$, $NHCONH_2$, $S(0)_2CH_3$, $COCH_3$.~~

~~16. A compound according to claim 1 wherein V is a direct bond.~~

~~17. A compound of formula (Xa)~~



(Xa)

wherein E is -C= or -N=;

R^9 and R^{10} are each independently one or more substituents selected from hydrogen, halogen, cyano, oxo, C_{1-4} alkyl, OC_{1-4} alkyl, or halo-C_{1-4} alkyl;

R^{11} is one or more substituents selected from hydrogen, halogen, cyano, cyclopropyl, C_{1-4} alkyl, or halo-C_{1-4} alkyl.

18. A compound according to claim 1 wherein R^1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more 3-7 membered cycloalkyl rings.

19. A compound according to claim 1 wherein W is a phenyl ring or a 5 or 6-membered heteroaryl ring, either ring being optionally substituted with one or more oxo substituents.

20. A compound according to claim 1 wherein R^3 is selected from C_{1-4} alkyl or C_{1-4} alkyl C_{1-4} alkoxy.

21. A compound according to claim 1 or claim 2 selected from:

3-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine (Example 1);

4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridine (Example 2);

4-({5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}methyl)morpholine (Example 3);

4-{6-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridazin-3-yl}morpholine (Example 4);

4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrazin-2-yl}morpholine (Example 5);

4-({5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-

~~yl]carbonyl)morpholine (Example 6);~~

~~5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-(oxan-4-yl)pyrazin-2-amine (Example 7);~~

~~1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-amine (Example 8);~~

~~*N*-(Cyclopropylmethyl)-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine (Example 9);~~

~~*N*-Cyclopropyl-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine (Example 10);~~

~~5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-(oxan-4-yl)pyrimidin-2-amine (Example 11);~~

~~4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}piperazin-2-one (Example 12);~~

~~4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}piperazin-2-one (Example 13);~~

~~5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-cyclopropylpyridine-2-carboxamide (Example 14);~~

~~3-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-(oxan-4-yl)pyridazine (Example 15);~~

~~*N*-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}methanesulfonamide (Example 16);~~

~~1-{4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-thiazol-2-yl}piperazine (Example 17);~~

~~1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-oxazol-2-yl}piperazine (Example 18);~~

~~1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-thiazol-2-yl}piperazine (Example 19);~~

~~5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-(oxan-4-yl)pyrimidin-2-amine (Example 20);~~

~~4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 21);~~

~~4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 22);~~

(2R,6S)-4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,6-dimethylmorpholine (Example 23);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-2,2-dimethylmorpholine (Example 24);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-1,4-oxazepane (Example 25);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl}morpholine (Example 26);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyrimidin-2-yl}morpholine (Example 27);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methoxypyridin-2-yl}morpholine (Example 28);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4,6-dimethylpyridin-2-yl}morpholine (Example 29);

2-Cyclopropyl-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidine (Example 30);

5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine (Example 31);

4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one (Example 32);

5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one (Example 33);

4-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,2-dihydropyridin-2-one (Example 34);

5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,2-dihydropyridin-2-one (Example 35);

(2R,6S)-2,6-Dimethyl-4-{5-[3-(5-methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 36);

N-(3-Methoxypropyl)-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine (Example 37);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-[2-(propan-2-yloxy)ethyl]pyrimidin-2-amine (Example 38);

5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-[2-(propan-2-yloxy)ethyl]pyrimidin-2-amine (Example 39);

~~4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}-1-methylpiperazin-2-one (Example 40);~~

~~4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 41);~~

~~N-(2-Ethoxyethyl)-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine (Example 42);~~

~~N-(2-Ethoxyethyl)-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine (Example 43);~~

~~5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-imidazole (Example 44);~~

~~1-({3-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)-4-methylpiperazine (Example 45);~~

~~1-({4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)-4-methylpiperazine (Example 46);~~

~~4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 47);~~

~~1-({4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)-1H-imidazole (Example 48);~~

~~4-({4-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]phenyl}methyl)morpholine (Example 49);~~

~~1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazine (Example 50);~~

~~4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 51);~~

~~4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 52);~~

~~4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 53);~~

~~4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 54);~~

~~4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 55);~~

~~4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-~~

yl]morpholine (Example 56);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 57);

4-{5-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 58);

4-{5-[3-(4-Bromophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 59);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 60);

4-{5-[3-(2-Chloro-4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 61);

4-{5-[3-(4-Fluoro-2-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 62);

4-{5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 63);

4-{5-[3-(6-Methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 64);

4-{2-[6-(Morpholin-4-yl)pyridin-3-yl]-3H-imidazo[4,5-c]pyridin-3-yl}phenol (Example 65);

4-(5-{3-[4-(Trifluoromethyl)phenyl]-3H-imidazo[4,5-c]pyridin-2-yl}pyridin-2-yl)morpholine (Example 66);

4-{5-[3-(2-Fluoro-4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 67);

4-{5-[3-(2-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 68);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine (Example 69);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-2-methylmorpholine (Example 70);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*,*N*-dimethylpyridin-2-amine (Example 71);

5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*,*N*-dimethylpyrimidin-2-amine (Example 72);

4-{4-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 73);

4-{5-[3-(4-Chloro-3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 74);

4-{5-[3-(5-Chloropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 75);

4-{5-[3-(5-Fluoropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 76);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 77);

4-{5-[3-(2,4-Difluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 78);

4-{5-[3-(5-Methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 79);

4-{5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 80);

4-{5-[3-(5-Chloropyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 81);

4-{5-[3-(5-Methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 82);

5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(pyrrolidin-1-yl)pyrimidine(Example 83);

5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*,*N*-dimethylpyrimidin-2-amine(Example 84);

N-(1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-yl)acetamide (Example 85);

1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one (Example 86);

1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl)-1,4-diazepan-1-yl)ethan-1-one; bis(trifluoroacetic acid) (Example 87);

~~*N*-(1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-yl)methanesulfonamide~~

~~(Example 88);~~

~~1-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine~~

~~(Example 89);~~

~~4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazine-1-carboxamide (Example 90);~~

~~(1-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperidin-4-yl)urea (Example 91);~~

~~4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazine-1-carboxamide (Example 92);~~

~~4-{5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,3-oxazol-2-yl}piperazine-1-carboxamide (Example 93);~~

~~4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-1,4-diazepane-1-carboxamide (Example 94);~~

~~4-(5-{3-Phenyl-3H-imidazo[4,5-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 95);~~

~~4-{5-[3-(4-Cyclopropylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 96);~~

~~4-{4-Methyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 97);~~

~~4-{3-Fluoro-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 98);~~

~~5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(morpholin-4-yl)-1,4-dihydropyridin-4-one (Example 99);~~

~~5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methyl-*N*-(oxan-4-yl)pyridin-2-amine (Example 100);~~

~~*N*-(Cyclopropylmethyl)-5-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methylpyridin-2-amine (Example 101);~~

~~5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-4-methyl-2-(1H-pyrazol-1-yl)pyridine (Example 102);~~

(2R,6S)-2,6-Dimethyl-4-{5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 103);

(2R,6S)-2,6-Dimethyl-4-{5-[3-(5-methylpyridin-2-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 104);

5-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-amine (Example 105);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-1-methylpiperazin-2-one (Example 106);

4-{4-Methyl-5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine (Example 107);

4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-6-methylpyridin-2-yl}morpholine (Example 108);

4-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*,*N*-dimethylpyridin-2-amine (Example 109);

5-[3-(4-Chlorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-amine (Example 110);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*,*N*,4-trimethylpyridin-2-amine (Example 111);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(oxolan-3-yloxy)pyridine (Example 112);

5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-2-(oxan-4-yloxy)pyridine (Example 113);

4-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one (Example 114);

1-Cyclopropyl-4-[3-(4-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1,2-dihydropyridin-2-one (Example 115);

4-[3-(4-Chloro-2-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1-cyclopropyl-1,2-dihydropyridin-2-one (Example 116);

N-(2-Methoxyethyl)-*N*-methyl-5-[3-(4-methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-amine (Example 117);

(2R,6S)-2,6-Dimethyl-4-{5-[3-(6-methylpyridin-3-yl)-3H-imidazo[4,5-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 118);

5-[3-(4-Methylphenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-*N*-(oxan-4-yl)pyrimidin-2-amine

and pharmaceutically acceptable salts thereof.

22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21, and one or more suitable excipients.

23. A compound according to any one of claims 1 to 21 for use in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

24. A method for the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth, which comprises administering to a subject suffering such disease an effective amount of a compound of formula (I) as claimed in any of claims 1 to 21.

25. A compound according to claim 23 or method according to claim 24 wherein the inflammation or inflammatory disease or immune or autoimmune disorder is arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and psoriatic arthritis), synovitis, vasculitis, Sjogren's disease, a condition associated with inflammation of the bowel (including Crohn's disease, ulcerative colitis, inflammatory bowel disease and irritable bowel syndrome), atherosclerosis, multiple sclerosis, Alzheimer's disease, vascular dementia, Parkinson's disease, cerebral amyloid angiopathy, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, a pulmonary inflammatory disease (including asthma, chronic obstructive pulmonary disease and acute respiratory distress syndrome), a fibrotic disease (including idiopathic pulmonary fibrosis, cardiac fibrosis, liver fibrosis and systemic sclerosis (scleroderma)), an inflammatory disease of the skin (including contact dermatitis, atopic dermatitis and psoriasis), an inflammatory disease of the eye (including age-related macular degeneration, uveitis and diabetic retinopathy), systemic inflammatory response syndrome, sepsis, an inflammatory and/or autoimmune condition of the liver (including autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, sclerosing cholangitis, and autoimmune cholangitis), diabetes (type I or II) and/or the complications thereof,

chronic heart failure, congestive heart failure, an ischemic disease (including stroke and ischemia-reperfusion injury) or myocardial infarction and/or the complications thereof, or epilepsy.

26. A compound according to claim 23 or method according to claim 24 for treatment of a disease selected from rheumatoid arthritis, osteoarthritis, liver fibrosis, chronic obstructive pulmonary disease, multiple sclerosis, Sjogren's disease, Alzheimer's disease, Parkinson's disease, inflammatory bowel disease, or vascular dementia.

27. A compound of formula (I), or a pharmaceutically acceptable salt, or N-oxide thereof wherein:

X is $-C(R^2)=$;

R^2 is selected from hydrogen, halogen, cyano, C_{1-4} alkyl, halo-C_{1-4} alkyl, cyano-C_{1-4} alkyl, $-OR^5$, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, $-SO_2R^5$, $-SO_2NR^{4A}R^{4B}$ and $-NR^6S(O)_2R^5$;

Y, Z, R^1, W, V, R^3 are as defined in claim 1,

PROVIDED THAT groups $-WVR^3$ and/or R^1 are not: and



wherein

n is 0, 1, or 2;

R' and R" are independently selected from the group consisting of H, C_1-C_6alkyl, $-(C=O)$-C_1-C_6 alkyl and $-(C=O)OC(CH_3)_3$; and

R"' is H, OH, or C_1-C_6 alkyl.

28. A compound of formula (I), or a pharmaceutically acceptable salt, or N-oxide thereof wherein:

X is $-C(R^2)=$;

~~R^2 is selected from hydrogen, halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, $-OR^5$, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, $-SO_2R^5$, $-SO_2NR^{4A}R^{4B}$ and $-NR^6S(O)_2R^5$; and Y, Z, R^1, W, V, R^3 are as defined in claim 2.~~

~~29. A compound according to claim 27 or claim 28 selected from:~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine (Example 120);~~

~~2-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine (Example 121);~~

~~3-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine (Example 122);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidine (Example 123);~~

~~2-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrazine (Example 124);~~

~~1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]phenyl}carbonyl)-4-methylpiperazine (Example 125);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-2,4-dimethyl-1H-imidazole (Example 126);~~

~~4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 127);~~

~~4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}piperazin-2-one (Example 128);~~

~~4-{5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-4-methylpyridin-2-yl}morpholine (Example 129);~~

~~4-{5-[1-(4-Methylphenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 130);~~

~~4-(5-{1-Phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl}pyrimidin-2-yl)morpholine (Example 131);~~

~~4-{5-[1-(5-Methylpyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 132);~~

~~4-{5-[1-(4-Bromophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyrimidin-2-yl}morpholine (Example 133);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1H-pyrazole (Example 134);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1H-pyrazole (Example 135);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1H-imidazole (Example 136);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-*N*,*N*-dimethylpyrimidin-2-amine (Example 137);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-cyclopropyl-1,2-dihydropyridin-2-one (Example 138);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-*N*-(oxan-4-yl)pyrimidin-2-amine (Example 139);~~

~~4-({5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridin-2-yl}methyl)morpholine (Example 140);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-4-methylpyridin-2-amine (Example 141);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1,2-dihydropyridin-2-one (Example 142);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one (Example 143);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-ethyl-1,2-dihydropyridin-2-one (Example 144);~~

~~6-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-1-methyl-1,2-dihydropyridin-2-one (Example 145);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-2,3-dihydropyridazin-3-one (Example 146);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridin-2-amine (Example 147);~~

~~3-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-5-fluoropyridine (Example 148);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-*N*-(cyclopropylmethyl)pyrimidin-2-amine (Example 149);~~

~~3-Chloro-5-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine (Example 150);~~

~~5-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-2-(1H-pyrazol-1-yl)pyridine (Example 151);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-3-fluoropyridine (Example 152);~~

~~3-Chloro-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]pyridine (Example 153);~~

~~4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-2-yl]-3-methylpyridine (Example 154);~~

1-Cyclopropyl-4-[1-phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl]-1,2-dihydropyridin-2-one (Example 155); or
a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising a compound according to any one of claims 26 to 29, and one or more suitable excipients.

31. A compound according to any one of claims 26 to 29 for use in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

32. A method for the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth, which comprises administering to a subject suffering such disease an effective amount of a compound of formula (I) as claimed in any of claims 26 to 29.

33. A compound according to claim 31 or method according to claim 32 wherein the inflammation or inflammatory disease or immune or autoimmune disorder is arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and psoriatic arthritis), synovitis, vasculitis, Sjogren's disease, a condition associated with inflammation of the bowel (including Crohn's disease, ulcerative colitis, inflammatory bowel disease and irritable bowel syndrome), atherosclerosis, multiple sclerosis, Alzheimer's disease, vascular dementia, Parkinson's disease, cerebral amyloid angiopathy, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, a pulmonary inflammatory disease (including asthma, chronic obstructive pulmonary disease and acute respiratory distress syndrome), a fibrotic disease (including idiopathic pulmonary fibrosis, cardiac fibrosis, liver fibrosis and systemic sclerosis (scleroderma)), an inflammatory disease of the skin (including contact dermatitis, atopic dermatitis and psoriasis), an inflammatory disease of the eye (including age-related macular degeneration, uveitis and diabetic retinopathy), systemic inflammatory response syndrome, sepsis, an inflammatory and/or autoimmune condition of the liver (including autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, sclerosing cholangitis, and

~~autoimmune cholangitis), diabetes (type I or II) and/or the complications thereof, chronic heart failure, congestive heart failure, an ischemic disease (including stroke and ischemia-reperfusion injury) or myocardial infarction and/or the complications thereof, or epilepsy.~~

~~34. A compound according to claim 31 or method according to claim 32 for treatment of a disease selected from rheumatoid arthritis, osteoarthritis, liver fibrosis, chronic obstructive pulmonary disease, multiple sclerosis, Sjogren's disease, Alzheimer's disease, Parkinson's disease, inflammatory bowel disease, or vascular dementia.~~